VAXCYTE, INC. Depreciation and Amortization Expense
VAXCYTE, INC. (PCVX) reported Depreciation and Amortization Expense of $16.40 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:DepreciationAndAmortization · last filed 2026-02-24
- VAXCYTE, INC. depreciation, depletion and amortization, nonproduction for the quarter ending 2024-12-31 was $2.90M, a 222.22% increase year-over-year.
- VAXCYTE, INC. depreciation, depletion and amortization, nonproduction for the quarter ending 2024-09-30 was $1.80M, a 125.00% increase year-over-year.
- VAXCYTE, INC. depreciation, depletion and amortization, nonproduction for the quarter ending 2024-06-30 was $1.40M, a 75.00% increase year-over-year.
- VAXCYTE, INC. depreciation, depletion and amortization, nonproduction for the quarter ending 2024-03-31 was $1.00M, a 42.86% increase year-over-year.
- VAXCYTE, INC. depreciation, depletion and amortization, nonproduction for fiscal 2025 was $16.40M, a 134.29% increase from fiscal 2024.
- VAXCYTE, INC. depreciation, depletion and amortization, nonproduction for fiscal 2024 was $7.00M, a 118.75% increase from fiscal 2023.
- VAXCYTE, INC. depreciation, depletion and amortization, nonproduction for fiscal 2023 was $3.20M, a 23.08% increase from fiscal 2022.
- VAXCYTE, INC. depreciation, depletion and amortization, nonproduction for fiscal 2022 was $2.60M, a 44.44% increase from fiscal 2021.
| Period end | Depreciation, Depletion and Amortization, Nonproduction 3 month | Depreciation, Depletion and Amortization, Nonproduction 6 month | Depreciation, Depletion and Amortization, Nonproduction 9 month | Depreciation, Depletion and Amortization, Nonproduction 12 month |
|---|---|---|---|---|
| 2025-12-31 | $16.40M 10-K · filed 2026-02-24 | |||
| 2024-12-31 | $2.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $4.70M derived: sum of 2 quarters · filed 2026-02-24 | $6.10M derived: sum of 3 quarters · filed 2026-02-24 | $7.00M 10-K · filed 2026-02-24 |
| 2024-09-30 | $1.80M 10-Q · filed 2024-11-05 | $3.20M derived: sum of 2 quarters · filed 2024-11-05 | $4.10M 10-Q · filed 2024-11-05 | $5.10M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $1.40M 10-Q · filed 2024-08-06 | $2.40M 10-Q · filed 2024-08-06 | $3.30M derived: sum of 3 quarters · filed 2026-02-24 | $4.10M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $1.00M 10-Q · filed 2024-05-08 | $1.90M derived: sum of 2 quarters · filed 2026-02-24 | $2.70M derived: sum of 3 quarters · filed 2026-02-24 | $3.50M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $900.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $1.70M derived: sum of 2 quarters · filed 2026-02-24 | $2.50M derived: sum of 3 quarters · filed 2026-02-24 | $3.20M 10-K · filed 2026-02-24 |
| 2023-09-30 | $800.00K 10-Q · filed 2024-11-05 | $1.60M derived: sum of 2 quarters · filed 2024-11-05 | $2.30M 10-Q · filed 2024-11-05 | $3.00M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $800.00K 10-Q · filed 2024-08-06 | $1.50M 10-Q · filed 2024-08-06 | $2.20M derived: sum of 3 quarters · filed 2025-02-25 | $2.90M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $700.00K 10-Q · filed 2024-05-08 | $1.40M derived: sum of 2 quarters · filed 2025-02-25 | $2.10M derived: sum of 3 quarters · filed 2025-02-25 | $2.70M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $700.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $1.40M derived: sum of 2 quarters · filed 2025-02-25 | $2.00M derived: sum of 3 quarters · filed 2025-02-25 | $2.60M 10-K · filed 2025-02-25 |
| 2022-09-30 | $700.00K 10-Q · filed 2023-11-06 | $1.30M derived: sum of 2 quarters · filed 2023-11-06 | $1.90M 10-Q · filed 2023-11-06 | $2.40M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $600.00K 10-Q · filed 2023-08-08 | $1.20M 10-Q · filed 2023-08-08 | $1.70M derived: sum of 3 quarters · filed 2024-02-27 | $2.20M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $600.00K 10-Q · filed 2023-05-08 | $1.10M derived: sum of 2 quarters · filed 2024-02-27 | $1.60M derived: sum of 3 quarters · filed 2024-02-27 | $2.10M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $1.00M derived: sum of 2 quarters · filed 2024-02-27 | $1.50M derived: sum of 3 quarters · filed 2024-02-27 | $1.80M 10-K · filed 2024-02-27 |
| 2021-09-30 | $500.00K 10-Q · filed 2022-11-07 | $1.00M derived: sum of 2 quarters · filed 2022-11-07 | $1.30M 10-Q · filed 2022-11-07 | $1.60M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $500.00K 10-Q · filed 2022-08-08 | $800.00K 10-Q · filed 2022-08-08 | $1.10M derived: sum of 3 quarters · filed 2023-02-27 | $1.40M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $300.00K 10-Q · filed 2022-05-09 | $600.00K derived: sum of 2 quarters · filed 2023-02-27 | $900.00K derived: sum of 3 quarters · filed 2023-02-27 | $1.30M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $600.00K derived: sum of 2 quarters · filed 2023-02-27 | $1.00M derived: sum of 3 quarters · filed 2023-02-27 | $1.40M 10-K · filed 2023-02-27 |
| 2020-09-30 | $300.00K 10-Q · filed 2021-11-10 | $700.00K derived: sum of 2 quarters · filed 2021-11-10 | $1.10M 10-Q · filed 2021-11-10 | $1.40M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $400.00K 10-Q · filed 2021-08-11 | $700.00K 10-Q · filed 2021-08-11 | $1.10M derived: sum of 3 quarters · filed 2022-02-28 | $1.40M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $400.00K 10-Q · filed 2021-05-11 | $700.00K derived: sum of 2 quarters · filed 2022-02-28 | $1.00M derived: sum of 3 quarters · filed 2022-02-28 | $1.30M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $600.00K derived: sum of 2 quarters · filed 2022-02-28 | $900.00K derived: sum of 3 quarters · filed 2022-02-28 | $1.20M 10-K · filed 2022-02-28 |
| 2019-09-30 | $300.00K 10-Q · filed 2020-11-12 | $600.00K derived: sum of 2 quarters · filed 2020-11-12 | $900.00K 10-Q · filed 2020-11-12 | |
| 2019-06-30 | $300.00K 10-Q · filed 2020-08-12 | $600.00K 10-Q · filed 2020-08-12 | ||
| 2018-12-31 | $1.00M 10-K · filed 2021-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |